Lumvoa's First Launch Quarter Brings $24.7M, Beating Management's Own Expectations
VRDN has more than doubled off its 52-week low of $13.18 on elevated volume (2.2× avg).
Summary
Viridian's first commercial quarter for Lumvoa in thyroid eye disease generated $25.8 million in net product revenue, with more than 100 patients on therapy as of September 30. Management said the launch has exceeded expectations, and CMS granted a permanent J-code effective January 1, 2027, which should smooth reimbursement. The company ended the quarter with $955.2 million in cash and says that plus future Lumvoa and elegrobart revenue funds the business through profitability, though the Q3 net loss widened to $101.2 million from $34.6 million a year ago on commercial build-out, a loss of 81 cents a share. Next up: elegrobart BLA submission targeted for Q1 2027, VRDN-292 phase 1 initiation in Q4 2026, and VRDN-008 phase 1 data plus FcRn portfolio plans in Q4 2026. The 8:00 a.m. ET call today will carry the launch trajectory detail.
At the time of this announcement, VRDN was trading at $27.09 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.8B. The 52-week trading range was $13.18 to $34.29. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: BusinessWire.